Sales of heart failure medication Entresto fell short of expectations, while closely watched cancer drug Pluvicto only beat estimates because of a one-time gain. The results pushed Novartis shares ...

Novartis raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped ...

While Novartis provided an optimistic take on 2024, the lack of commentary on 2025 “may disappoint,” Bloomberg Intelligence ...

Total net sales at Novartis AG grew by 10% to $12.8bn (€11.9bn ... The highest-selling medicines of the company, included the ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis reported a mixed third quarter on Tuesday, as the pharmaceutical giant lifted its profit outlook for the year but ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss ...

Sales of heart failure medication Entresto fell short of expectations, while closely watched cancer drug Pluvicto only beat estimates because of a one-time gain. Novartis shares fell as much as 4. ...

Novartis forecasts full-year sales growth ... and volume growth in core indications. Heart failure drug Entresto sales increased 26% to $1.87 billion, a demand-led growth. The drug has increased ...